Latest Distributions News

Latin Resources has secured shareholder and court approvals for its acquisition by Pilbara Minerals, marking a pivotal transition for the Salinas Lithium Project in Brazil. The deal positions Salinas as a key global lithium asset under new stewardship.

Following a recent unitholder meeting, One Managed Investment Funds Limited has initiated the orderly liquidation of the Fat Prophets Global Property Fund’s portfolio, signaling a significant transition for investors.

Uscom Limited reports a 56% increase in cash on hand to $2.17 million for Q2 2024, driven by strategic moves in China and new product regulatory approvals.

Mesoblast Limited is set to launch Ryoncil®, the first FDA-approved MSC therapy for pediatric steroid-refractory acute graft-versus-host disease, backed by a recent $160 million financing that strengthens its commercial and clinical development efforts.

Prophecy International has inked a three-year global reseller agreement with US SIEM leader Securonix, aiming to generate over $1 million in new annual recurring revenue within the first year.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.

Adslot Ltd reports a robust Q2 FY25 with significant contract wins for its StoreFront platform and a 43% quarter-on-quarter increase in monetised transaction value, despite ongoing challenges in the Australian market.

NoviqTech's December quarter report reveals a strategic $1.05 million capital raise, a significant HBAR token purchase, and expanding partnerships that position the company at the forefront of blockchain-powered sustainability solutions.

ResMed Inc. has announced a quarterly ordinary dividend of USD 0.053 per share for holders of its ASX-listed Chess Depositary Instruments, with payments scheduled for March 2025.

INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.

Enlitic reported a robust 41.1% increase in quarterly revenue alongside the completion of its strategic acquisition of Laitek, positioning the company for operational cash flow break-even by the end of 2025.